卵巢Brenner瘤研究进展

doi:10.12280/gjfckx.20220427

摘要/Abstract

摘要：

卵巢Brenner瘤是卵巢肿瘤的罕见病理类型，可分为良性、交界性/非典型增殖性及恶性。其病因及发病机制尚不明确，临床表现及影像学检查无特异性，术前易误诊，确诊主要依靠术后病理学检查。近年研究发现卵巢恶性Brenner瘤（malignant Brenner tumor，MBT）由卵巢良性Brenner瘤逐渐进展而来，且发生过程与成纤维细胞生长因子受体3（fibroblast growth factor receptor 3，FGFR3）、CCND1、鼠双微体基因2（murine double minute 2，MDM2）、细胞周期蛋白依赖性激酶抑制因子2A（cyclin-dependent kinase inhibitor 2A，CDKN2A）及磷脂酰肌醇3激酶催化亚基ɑ（phosphoinositide 3-kinase catalytic alpha polypeptide，PIK3CA）等基因变异有关。卵巢Brenner瘤的治疗以手术为主，其中卵巢MBT术后可辅以铂类-紫杉醇方案化疗，并有望针对其致癌位点进行靶向治疗，而分期是重要的预后因素，早诊断、早治疗是改善预后的关键。

关键词: 卵巢肿瘤, Brenner瘤, 基因, 突变, 诊断, 治疗

Abstract:

Ovarian Brenner tumor is a rare pathological type of ovarian tumor, which can be divided into benign, borderline/atypical proliferalive and malignant. Its etiology and pathogenesis are still unclear, the clinical manifestations and imaging examinations are not specific, and it is easy to misdiagnose before surgery, and the diagnosis mainly depends on postoperative pathological examination. Recent studies have found that malignant Brenner tumor (MBT) gradually progresses from benign Brenner tumor of the ovaries, and the process of occurrence is related to the genetic variants of fibroblast growth factor receptor 3 (FGFR3) gene, CCND1 gene, and murine double microbody gene 2 (MDM2), cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and phosphoinositide 3-kinase catalytic alpha polypeptide (PIK3CA) gene. The treatment of ovarian Brenner tumor is mainly surgery, in which ovarian MBT can be supplemented with platinum-paclitaxel chemotherapy after surgery, and it is expected to be targeted therapy for its carcinogenic sites. Staging is an important prognostic factor, and early diagnosis and treatment is the key to improve prognosis.

Key words: Ovarian neoplasms, Brenner tumor, Genes, Mutation, Diagnosis, Therapy

万桃, 俞萍源, 邢义涓, 王黎, 杨永秀. 卵巢Brenner瘤研究进展[J]. 国际妇产科学杂志, 2023, 50(1): 20-24.

WAN Tao, YU Ping-yuan, XING Yi-juan, WANG Li, YANG Yong-xiu. Research Progress of Ovarian Brenner Tumor[J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 20-24.

参考文献 31

[1]	Turgay B, Koyuncu K, Taşkin S, et al. Features of ovarian Brenner tumors: Experience of a single tertiary center[J]. Turk J Obstet Gynecol, 2017, 14(2):133-137. doi: 10.4274/tjod.98216. doi: 10.4274/tjod.98216 pmid: 28913150
[2]	Lang SM, Mills AM, Cantrell LA. Malignant Brenner tumor of the ovary: Review and case report[J]. Gynecol Oncol Rep, 2017, 22:26-31. doi: 10.1016/j.gore.2017.07.001. doi: 10.1016/j.gore.2017.07.001
[3]	Kuhn E, Ayhan A, IeM S, et al. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium[J]. Eur J Cancer, 2013, 49(18):3839-3849. doi: 10.1016/j.ejca.2013.08.011. doi: 10.1016/j.ejca.2013.08.011 pmid: 24012099
[4]	Shetty S, Habeeb O, Rivera C, et al. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas[J]. Hum Pathol, 2021, 117:42-50. doi: 10.1016/j.humpath.2021.08.001. doi: 10.1016/j.humpath.2021.08.001 pmid: 34391746
[5]	Roma AA, Masand RP. Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study[J]. Hum Pathol, 2014, 45(12):2417-2422. doi: 10.1016/j.humpath.2014.08.003. doi: 10.1016/j.humpath.2014.08.003 pmid: 25281026
[6]	Toboni MD, Smith HJ, Dilley SE, et al. Malignant Brenner tumor associated with a germline BRCA2 mutation[J]. Gynecol Oncol Rep, 2017, 21:17-19. doi: 10.1016/j.gore.2017.05.006. doi: 10.1016/j.gore.2017.05.006
[7]	Cuatrecasas M, Catasus L, Palacios J, et al. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas[J]. Am J Surg Pathol, 2009, 33(4):556-567. doi: 10.1097/PAS.0b013e318188b84c. doi: 10.1097/PAS.0b013e318188b84c pmid: 19033864
[8]	Parcesepe P, Coppola L, Remo A, et al. Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report[J]. Front Oncol, 2021, 11:663489. doi: 10.3389/fonc.2021.663489. doi: 10.3389/fonc.2021.663489
[9]	Lin DI, Killian JK, Venstrom JM, et al. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary[J]. Mod Pathol, 2021, 34(5):983-993. doi: 10.1038/s41379-020-00699-1. doi: 10.1038/s41379-020-00699-1
[10]	Hisaoka M, Schott J, Bortecen T, et al. Preferential translation of p53 target genes[J]. RNA Biol, 2022, 19(1):437-452. doi: 10.1080/15476286.2022.2048562. doi: 10.1080/15476286.2022.2048562 pmid: 35388737
[11]	Pfarr N, Darb-Esfahani S, Leichsenring J, et al. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology[J]. Genes Chromosomes Cancer, 2017, 56(10):758-766. doi: 10.1002/gcc.22480. doi: 10.1002/gcc.22480
[12]	Kuhn E, Ayhan A, IeM S, et al. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis[J]. Mod Pathol, 2014, 27(2):231-237. doi: 10.1038/modpathol.2013.142. doi: 10.1038/modpathol.2013.142
[13]	Wang L, Allison D, Shukla PS. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?[J]. Am J Clin Pathol, 2020, 154(1):133-141. doi: 10.1093/ajcp/aqaa033. doi: 10.1093/ajcp/aqaa033 pmid: 32322877
[14]	Yüksel D, Kılıç C, Çakır C, et al. Brenner tumors of the ovary: clinical features and outcomes in a single-center cohort[J]. J Turk Ger Gynecol Assoc, 2022, 23(1):22-27. doi: 10.4274/jtgga.galenos.2021.2021.0001. doi: 10.4274/jtgga.galenos.2021.2021.0001
[15]	郜亚娟, 刘达, 崔满华. 卵巢透明细胞腺癌伴恶性Brenner瘤一例报告[J]. 国际妇产科学杂志, 2018, 45(3):358-360. doi: 10.3969/j.issn.1674-1870.2018.03.029. doi: 10.3969/j.issn.1674-1870.2018.03.029
[16]	Myroshnychenko MS, Dyadyk OO, Urzhumov VD, et al. Clinical and morphological features of the ovarian brenner tumour: current state of the problem[J]. Wiad Lek, 2020, 73(7):1420-1426. pmid: 32759431
[17]	Singh BK, Saha S, Agarwal S, et al. Malignant Brenner tumour of the ovary manifesting as distal intestinal obstruction and perforation[J]. BMJ Case Rep, 2020, 13(6):e235394. doi: 10.1136/bcr-2020-235394. doi: 10.1136/bcr-2020-235394
[18]	Aboubakari AS, Dossouvi T, Logbo-Akey KE, et al. Demons meigs′ syndrome secondary to begnin brenner tumor with high ca125 plasmatic level: first case described in kara teaching hospital[J]. O J Gyencol Obset Res, 2019, 1:8-12. doi: 10.36811/ojgor.2019.110002. doi: 10.36811/ojgor.2019.110002
[19]	Bagga R, Pandit R, Saha PK, et al. A Rare Case of Grade 1 Endometrioid Adenocarcinoma of the Uterus With Omental Metastasis with Brenner Tumor of the Ovary in a Postmenopausal Female[J]. J Midlife Health, 2020, 11(1):45-48. doi: 10.4103/jmh.JMH_141_18. doi: 10.4103/jmh.JMH_141_18 pmid: 32684728
[20]	Nasioudis D, Sisti G, Holcomb K, et al. Malignant Brenner tumors of the ovary; a population-based analysis[J]. Gynecol Oncol, 2016, 142(1):44-49. doi: 10.1016/j.ygyno.2016.04.538. doi: S0090-8258(16)30671-0 pmid: 27130406
[21]	魏晓光, 张爱青, 王威, 等. 卵巢Brenner瘤的超声诊断研究[J]. 中国超声医学杂志, 2021, 37(5):574-576. doi: 10.3969/j.issn.1002-0101.2021.05.030. doi: 10.3969/j.issn.1002-0101.2021.05.030
[22]	Matsutani H, Nakai G, Yamada T, et al. MRI and FDG PET/CT Findings for Borderline Brenner Tumor of the Ovary: A Case Report and Literature Review[J]. Case Rep Obstet Gynecol, 2020, 2020:8878649. doi: 10.1155/2020/8878649. doi: 10.1155/2020/8878649
[23]	钟萍萍, 朱力, 张立红, 等. 卵巢Brenner肿瘤的临床病理分析[J]. 中华病理学杂志, 2019, 48(8):615-619. doi: 10.3760/cma.j.issn.0529-5807.2019.08.006. doi: 10.3760/cma.j.issn.0529-5807.2019.08.006
[24]	毕玉晰, 李洋洋, 蒋杰, 等. 卵巢恶性Brenner瘤一例报告并文献复习[J]. 国际妇产科学杂志, 2018, 45(4):473-476. doi: 10.3969/j.issn.1674-1870.2018.04.026. doi: 10.3969/j.issn.1674-1870.2018.04.026
[25]	阳云金, 任黔川. 卵巢纤维瘤的临床病理分析[J]. 实用临床医学, 2016, 17(3):44-47,68,封4. doi: 10.13764/j.cnki.lcsy.2016.03.018. doi: 10.13764/j.cnki.lcsy.2016.03.018
[26]	Ricotta G, Maulard A, Genestie C, et al. Brenner Borderline Ovarian Tumor: A Case Series and Literature Review[J]. Ann Surg Oncol, 2021, 28(11):6714-6720. doi: 10.1245/s10434-021-09879-y. doi: 10.1245/s10434-021-09879-y pmid: 33768396
[27]	Zheng R, Heller DS. Borderline Brenner Tumor: A Review of the Literature[J]. Arch Pathol Lab Med, 2019, 143(10):1278-1280. doi: 10.5858/arpa.2018-0285-RS. doi: 10.5858/arpa.2018-0285-RS pmid: 30779594
[28]	Zhang Y, Staley SA, Tucker K, et al. Malignant Brenner tumor of the ovary: Case series and review of treatment strategies[J]. Gynecol Oncol Rep, 2019, 28:29-32. doi: 10.1016/j.gore.2019.02.003. doi: 10.1016/j.gore.2019.02.003
[29]	Gezginç K, Karatayli R, Yazici F, et al. Malignant Brenner tumor of the ovary: analysis of 13 cases[J]. Int J Clin Oncol, 2012, 17(4):324-329. doi: 10.1007/s10147-011-0290-7. doi: 10.1007/s10147-011-0290-7 pmid: 21796330
[30]	Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study[J]. Lancet Oncol, 2022,23(2):248-258. doi: doi: 10.1016/S1470-2045(21)00660-4. doi: 10.1016/S1470-2045(21)00660-4
[31]	王继超, 杨采彬, 卓伊琳, 等. MDM2-p53抑制剂的研究进展[J]. 药学学报, 2021, 56(4):983-995. doi: 10.16438/j.0513-4870.2020-1454. doi: 10.16438/j.0513-4870.2020-1454